Key Highlights

● FMC cut its regular quarterly dividend from 58 cents to 8 cents in October 2025.

● FMC shares closed at $8.35 on 9 October 2026, down 6.39% on the trading day.

● The trailing dividend yield is 3.83%, built from four regular payments of $0.08 per share.

● Management expects about $1 billion of proceeds for debt reduction from asset sales and equity.

FMC Corporation (NYSE:FMC) cut its regular quarterly dividend from 58 cents to 8 cents per share because the board wanted to prioritise debt reduction as earnings weakened. That reset, announced on 29 October 2025, is why the trailing dividend yield is a fraction of what older data suggest, and why the sustainability question now rests on balance-sheet repair rather than on the size of the cheque.

The yield and the payments

Using a closing price of $8.35 on 9 October 2026, FMC's trailing dividend yield is 3.83%. That figure is the sum of four regular payments of $0.08 per share, a total of $0.32, with ex-dividend dates from 10 October 2025 to 9 October 2026 inclusive: 31 December 2025, 31 March, 30 June and 30 September 2026. The most recent is payable on 15 October 2026. No special dividends fell in the window. Another market-data source shows an $8.36 close for the same day, a one-cent gap that does not change the rounded yield.

The latest declaration, made on 23 July 2026, is again 8 cents per share, with a record date of 30 September and payment on 15 October. Annualised at four payments a year, that is $0.32, an indicated regular yield of 3.83% at the same price.

Business and earnings

FMC develops and sells agricultural chemistry, including active ingredients such as diamides and formulated crop-protection products, and its ordinary shares are listed on the New York Stock Exchange. The past year has been difficult. In the second quarter of 2026 revenue fell 17% to $867.1 million, and the company reported a GAAP net loss attributable to shareholders of $186.6 million, or $1.49 per diluted share, after restructuring and other charges of $222.3 million. Adjusted earnings were $0.26 per share, down 62%, and adjusted EBITDA was $152.6 million.

Management lowered its 2026 guidance, excluding India, to adjusted earnings of $1.19 to $1.49 per share and adjusted EBITDA of $620 million to $680 million, citing price pressure and reduced diamide partner orders. Against that adjusted earnings range, the $0.32 annual dividend is roughly 22% to 27%, a modest share of profits on the company's own measure, though GAAP earnings are negative.

Cash flow and debt

Cash is the tighter constraint. Free cash flow was negative $270.7 million in the first half, and the second-quarter figure of $357.4 million included a $200 million upfront payment for a licence of the rimisoxafen herbicide to Corteva (NYSE:CTVA), so it should not be read as a run-rate. The 2026 free cash flow guidance of $75 million to $225 million includes the same payment. Dividends cost $10.2 million in the second quarter and $20.2 million in the half. Total debt was $4,280.6 million against cash of $476.6 million at 30 June, which implies net debt of about $3.8 billion.

Management expects about $1 billion of proceeds for debt reduction, including an agreed $252 million sale of the India commercial business, a $114 million sale-leaseback of the Newark, Delaware site, and a $400 million equity investment from Tessenderlo Group, which is subject to regulatory approvals. The board has also said its strategic review, announced in February 2026, has concluded.

Asset Sales and the Tessenderlo Investment Decide Whether the Payout Holds

Third-quarter adjusted EBITDA is guided to $120 million to $140 million and the fourth quarter to $275 million to $315 million, so the year depends heavily on the final months. The measures to follow are whether the asset sales and the Tessenderlo investment close on schedule, whether price pressure eases, and whether the board keeps the payment at 8 cents when it next declares. Shares closed at $8.35 on 9 October, down 6.39% on the day.